Is NeoGenomics Stock a Good Investment?
NeoGenomics Investment Advice | NEO |
- Examine NeoGenomics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NeoGenomics' leadership team and their track record. Good management can help NeoGenomics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact NeoGenomics' business and its evolving consumer preferences.
- Compare NeoGenomics' performance and market position to its competitors. Analyze how NeoGenomics is positioned in terms of product offerings, innovation, and market share.
- Check if NeoGenomics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NeoGenomics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NeoGenomics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NeoGenomics is a good investment.
Sell | Buy |
Sell
Market Performance | Weakest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine NeoGenomics Stock
Researching NeoGenomics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 97.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. NeoGenomics has Price/Earnings (P/E) ratio of 272.37. The entity recorded a loss per share of 0.82. The firm had not issued any dividends in recent years. NeoGenomics had 1:100 split on the 16th of April 2003.
To determine if NeoGenomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeoGenomics' research are outlined below:
| NeoGenomics generated a negative expected return over the last 90 days | |
| NeoGenomics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 660.57 M. Reported Net Loss for the year was (78.73 M) with profit before taxes, overhead, and interest of 302.24 M. | |
| NeoGenomics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from stockstory.org: 1 Small-Cap Stock with Exciting Potential and 2 We Ignore |
NeoGenomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeoGenomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeoGenomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact NeoGenomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises NeoGenomics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2011-10-19 | 2011-09-30 | -0.01 | -0.0033 | 0.0067 | 67 | ||
2015-07-23 | 2015-06-30 | -0.01 | -0.0029 | 0.0071 | 71 | ||
2013-02-14 | 2012-12-31 | -0.01 | -0.0023 | 0.0077 | 77 | ||
2009-07-28 | 2009-06-30 | 0.01 | 2.0E-4 | -0.0098 | 98 | ||
2025-07-29 | 2025-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2021-11-04 | 2021-09-30 | -0.09 | -0.08 | 0.01 | 11 | ||
2019-10-29 | 2019-09-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2019-07-30 | 2019-06-30 | 0.06 | 0.07 | 0.01 | 16 |
NeoGenomics Target Price Consensus
NeoGenomics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. NeoGenomics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Buy |
Most NeoGenomics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand NeoGenomics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of NeoGenomics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNeoGenomics Target Price Projection
NeoGenomics' current and average target prices are 6.10 and 11.25, respectively. The current price of NeoGenomics is the price at which NeoGenomics is currently trading. On the other hand, NeoGenomics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On NeoGenomics Target Price
NeoGenomics Analyst Ratings
NeoGenomics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about NeoGenomics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of NeoGenomics' financials, market performance, and future outlook by experienced professionals. NeoGenomics' historical ratings below, therefore, can serve as a valuable tool for investors.Know NeoGenomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as NeoGenomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading NeoGenomics backward and forwards among themselves. NeoGenomics' institutional investor refers to the entity that pools money to purchase NeoGenomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | American Century Companies Inc | 2025-03-31 | 3.3 M | T. Rowe Price Investment Management,inc. | 2025-03-31 | 3.3 M | Geode Capital Management, Llc | 2025-03-31 | 3.1 M | Segall Bryant & Hamill | 2025-03-31 | 2.4 M | Loomis, Sayles & Company Lp | 2025-03-31 | 1.8 M | Goldman Sachs Group Inc | 2025-03-31 | 1.7 M | Jennison Associates Llc | 2025-06-30 | 1.7 M | Northern Trust Corp | 2025-03-31 | 1.6 M | Fred Alger Management, Llc | 2025-03-31 | 1.6 M | Blackrock Inc | 2025-03-31 | 19.9 M | Vanguard Group Inc | 2025-03-31 | 14.3 M |
NeoGenomics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 751.82 M.Market Cap |
|
NeoGenomics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.11) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.09) | (0.08) |
Determining NeoGenomics' profitability involves analyzing its financial statements and using various financial metrics to determine if NeoGenomics is a good buy. For example, gross profit margin measures NeoGenomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeoGenomics' profitability and make more informed investment decisions.
Evaluate NeoGenomics' management efficiency
NeoGenomics has Return on Asset of (0.0325) % which means that on every $100 spent on assets, it lost $0.0325. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.1176) %, meaning that it generated no profit with money invested by stockholders. NeoGenomics' management efficiency ratios could be used to measure how well NeoGenomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 12th of August 2025, Return On Tangible Assets is likely to drop to -0.11. In addition to that, Return On Capital Employed is likely to grow to -0.07. At this time, NeoGenomics' Total Assets are very stable compared to the past year. As of the 12th of August 2025, Total Current Assets is likely to grow to about 625.8 M, while Other Assets are likely to drop about 3.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 35.62 | 37.40 | |
| Tangible Book Value Per Share | 1.57 | 1.37 | |
| Enterprise Value Over EBITDA | -1.5 K | -1.5 K | |
| Price Book Value Ratio | 0.46 | 0.44 | |
| Enterprise Value Multiple | (434.01) | (412.31) | |
| Price Fair Value | 0.46 | 0.44 | |
| Enterprise Value | 59.3 M | 39.4 M |
NeoGenomics benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Beta 1.539 |
Basic technical analysis of NeoGenomics Stock
As of the 12th of August 2025, NeoGenomics secures the Standard Deviation of 3.97, risk adjusted performance of (0.07), and Mean Deviation of 2.7. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NeoGenomics, as well as the relationship between them.NeoGenomics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeoGenomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeoGenomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeoGenomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeoGenomics' Outstanding Corporate Bonds
NeoGenomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NeoGenomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NeoGenomics bonds can be classified according to their maturity, which is the date when NeoGenomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TNEMAK 3625 28 JUN 31 Corp BondUS64045DAC83 | View | |
| US64049MAB63 Corp BondUS64049MAB63 | View |
Understand NeoGenomics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NeoGenomics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (992.08) | |||
| Standard Deviation | 3.97 | |||
| Variance | 15.74 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 24.44 | |||
| Value At Risk | (5.67) | |||
| Potential Upside | 4.92 | |||
| Skewness | (1.27) | |||
| Kurtosis | 6.33 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.15) | |||
| Mean Deviation | 2.7 | |||
| Coefficient Of Variation | (992.08) | |||
| Standard Deviation | 3.97 | |||
| Variance | 15.74 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.65) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.16) | |||
| Maximum Drawdown | 24.44 | |||
| Value At Risk | (5.67) | |||
| Potential Upside | 4.92 | |||
| Skewness | (1.27) | |||
| Kurtosis | 6.33 |
Consider NeoGenomics' intraday indicators
NeoGenomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NeoGenomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
NeoGenomics Corporate Filings
8K | 8th of August 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of July 2025 Other Reports | ViewVerify | |
| 16th of June 2025 Other Reports | ViewVerify |
NeoGenomics Stock media impact
There is far too much social signal, news, headlines, and media speculation about NeoGenomics that are available to investors today. This information is accessible both publicly - through NeoGenomics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of NeoGenomics-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of NeoGenomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeoGenomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeoGenomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeoGenomics alpha.
NeoGenomics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NeoGenomics Historical Investor Sentiment
Investor biases related to NeoGenomics' public news can be used to forecast risks associated with an investment in NeoGenomics. The trend in average sentiment can be used to explain how an investor holding NeoGenomics can time the market purely based on public headlines and social activities around NeoGenomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
NeoGenomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for NeoGenomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average NeoGenomics news discussions. The higher the estimate score, the more favorable the investor's outlook on NeoGenomics.
NeoGenomics Corporate Management
| Nathan MD | Vice Services | Profile | |
| George Cardoza | Pres Operations | Profile | |
| Gary Passman | Chief Officer | Profile | |
| Alicia Olivo | General Development | Profile | |
| Andrew Lukowiak | Chief Officer | Profile | |
| Cynthia Dieter | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.82) | Revenue Per Share | Quarterly Revenue Growth 0.102 | Return On Assets |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between NeoGenomics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.